Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
September 21, 2022 08:15 ET
|
Zealand Pharma
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) ...
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
September 19, 2022 02:00 ET
|
Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
September 07, 2022 02:00 ET
|
Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...
Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer
August 24, 2022 04:30 ET
|
Zealand Pharma
COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the...
Vyteris and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs
April 14, 2009 08:00 ET
|
Vyteris, Inc.
FAIR LAWN, NJ--(Marketwire - April 14, 2009) - Vyteris, Inc. (OTCBB: VYTR), developer of the
first FDA-approved active transdermal drug delivery system and a leader in
active transdermal drug...